Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PTE

PolarityTE (PTE) Stock Price, News & Analysis

PolarityTE logo

About PolarityTE Stock (NASDAQ:PTE)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.20
$0.57
52-Week Range
N/A
Volume
8.50 million shs
Average Volume
249,591 shs
Market Capitalization
$1.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PolarityTE, Inc., a clinical stage biotechnology company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine Products and Contract Services. It offers SkinTE, a tissue product used to repair, reconstruction, replacement, and supplementation of skin in patients for the treatment of acute or chronic wounds, burns, surgical reconstruction events, scar revision, or removal of dysfunctional skin grafts, as well as contract research services. The company also develops SkinTE Cryo allows multiple deployments from one original harvest through a cryopreservation process; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and other tissue regeneration products. PolarityTE, Inc. is headquartered in Salt Lake City, Utah.

Receive PTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolarityTE and its competitors with MarketBeat's FREE daily newsletter.

PTE Stock News Headlines

Regenetp Inc RGTPQ
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
RegenETP, Inc. (NJT.SG)
PolarityTE Stock (NASDAQ:PTE), Dividends
See More Headlines

PTE Stock Analysis - Frequently Asked Questions

PolarityTE, Inc. (NASDAQ:PTE) issued its earnings results on Wednesday, November, 10th. The company reported ($2.25) earnings per share for the quarter, beating the consensus estimate of ($3.00) by $0.75. The company had revenue of $1.12 million for the quarter, compared to analysts' expectations of $0.97 million.

PolarityTE's stock reverse split before market open on Tuesday, May 17th 2022. The 1-25 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that PolarityTE investors own include Bionano Genomics (BNGO), Acasti Pharma (ACST), T2 Biosystems (TTOO), SNDL (SNDL), Zomedica (ZOM), Tonix Pharmaceuticals (TNXP) and Vaxart (VXRT).

Company Calendar

Last Earnings
11/10/2021
Today
5/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:PTE
Employees
42
Year Founded
1986

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-7,830,000.00
Pretax Margin
-11,376.71%

Debt

Sales & Book Value

Annual Sales
$810,000.00
Price / Cash Flow
N/A
Book Value
$2.30 per share
Price / Book
N/A

Miscellaneous

Free Float
6,978,000
Market Cap
$1.78 million
Optionable
Optionable
Beta
1.15

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:PTE) was last updated on 5/9/2025 by MarketBeat.com Staff
From Our Partners